94467-73-9

Usage

Uses

Used in Pharmaceutical Industry:
Morpholin-4-yl-piperidin-4-yl-methanone hydrochloride is used as a key intermediate for the synthesis of various medications, including antihistamines and antipsychotic drugs. Its role in the production of these medications is crucial, as it contributes to the development of effective treatments for a range of health conditions.
Used in Research and Development:
In addition to its applications in the pharmaceutical industry, Morpholin-4-yl-piperidin-4-yl-methanone hydrochloride is also utilized in research and development for the creation of new drugs and chemical entities. Its unique properties make it a valuable component in the exploration of novel therapeutic agents and potential breakthroughs in medicine.

InChI:InChI=1/C10H18N2O2.ClH/c13-10(9-1-3-11-4-2-9)12-5-7-14-8-6-12;/h9,11H,1-8H2;1H

Upstream product

• 52482-36-7 morpholin-4-yl(pyridin-4-yl)methanone 
• 110-91-8 morpholine 
• 5984-56-5 piperidine-4-carboxylic acid hydrochloride 

Relevant academic research and scientific papers

Novel methanone derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating blindness related diseases containing the same as an active ingredient

The present invention relates to novel methanone derivatives, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating retinal diseases. Since the novel methanone derivatives according to the present invention, optical isomers thereof or pharmaceutically acceptable salts thereof have an excellent effect of inhibiting receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the composition comprising the same as an active ingredient can be advantageously used as a pharmaceutical composition for preventing or treating retinal diseases such as retinitis pigmentosa (RP), Leberandprime;s congenital amaurosis (LCA), Stargardts disease, Usher syndrome, choroideremia, rod-cone or cone-rod dystrophy, ciliopathies, a mitochondrial disorder, progressive retinal atrophy, a degenerative retinal disease, age-related macular degeneration (AMD), wet AMD, dry AMD, geographic atrophy, hereditary or acquired maculopathy, a retinal photoreceptor disease, a retinal pigment epithelial disease, diabetic retinopathy, cystic macular edema, uveitis, retinal detachment, traumatic retinal damage, iatrogenic retinal damage, a macular hole, macular capillary ectasia, a ganglion cell disease, an optic nerve disease, glaucoma, optic neuropathy, ischemic retinal disease , retinopathy of prematurity (ROP), retinal vascular occlusion, hereditary macroaneurysm, a retinal vascular disease , an ophthalmovascular disease, degeneration of retinal neuronal cells caused by glaucoma, or ischemic optic neuropathy.COPYRIGHT KIPO 2015

A highly efficient Pd-C catalytic hydrogenation of pyridine nucleus under mild conditions

A synergistic Pd-C catalytic hydrogenation of 4-pyridinecarboxamides straightforward to 4-piperidinecarboxamide hydrochlorides was developed in the presence of ClCH2CHCl2. It provided a novel strategy for highly efficient hydrogenati